Amphion Innovations (AMP)


LSE:AMP: Additional Terms on Loan Facility

Amphion Innovations

29 Apr 2016 16:02:58

Amphion Innovations

RNS Number : 8947W
Amphion Innovations PLC
29 April 2016

Amphion Innovations plc

 ("Amphion" or "the Company")

Additional Terms on Loan Facility

London and New York, 29 April 2016 - On 28 April, Amphion Innovations plc (AIM: AMP), the developer of medical, life science, and technology businesses, announced that the Company had agreed terms for the draw-down of an additional tranche of US $1,765,000 (an "Additional Draw") under the loan facility as announced on 5 June 2014 (the "Facility"). 

Additional terms of the Facility allow the conversion of the drawn-down amount into ordinary shares in Amphion ("Ordinary Shares").  Up to US $500,000 of the Facility may be converted at 6.5 pence per Ordinary Share and the remainder of the amount drawn-down under the Facility, approximately US $3.6 million, may be converted at 8.0 pence per Ordinary Share.


For further information please contact:


Amphion Innovations
Charlie Morgan
+1 212 210 6224

Yellow Jersey PR

Charles Goodwin / Dominic Barretto
+44 (0)7747 788 221

Panmure Gordon Limited (Nominated Adviser and Corporate Broker)

Freddy Crossley / Duncan Monteith (Corporate Finance)
Charlie Leigh-Pemberton (Corporate Broking)
+44 (0)20 7886 2500

Northland Capital Partners Limited (Joint Corporate Broker) 
Patrick Claridge / David Hignell (Corporate Finance)
John Howes (Corporate Broking)
+44 (0)20 7382 1100

Plumtree Capital Limited (Financial Adviser)
Stephen Austin
+44 (0)20 7183 2493
+646 568 7502


About Amphion Innovations plc


Amphion Innovations is a developer of medical, life science and technology businesses.


We use our extensive experience in company building to invest and build shareholder value in high growth companies in the US and UK. Amphion has significant shareholding in 7 Partner Companies developing proven technologies targeting substantial commercial marketplaces. The Amphion model has been refined to optimise the commercialisation of patents and other intellectual property within the Partner Companies. The Partner Companies collectively own or control over 200 separately identified pieces of intellectual property, a number which grows rapidly each year.


On the web: 


This information is provided by RNS
The company news service from the London Stock Exchange